1
Although morbidity and mortality are particularly high in low-and middle-income countries (LMICs), there are very little robust data on the true prevalence of asthma and COPD in these countries. 2, 3 Chronic respiratory symptoms are common in the general population, 1 but the clinicians in primary healthcare systems in resource-poor countries lack the skills and support to diagnose the underlying disease condition. [4] [5] [6] [7] [8] Factors contributing to low rates of diagnosis include limited awareness of respiratory long-term conditions, [4] [5] [6] [7] [8] [9] [10] limited access to healthcare and lack of diagnostic capability in these countries. 11 Determining the prevalence of asthma and COPD remains a challenge because of the poor sensitivity and specificity of the widely used questionnaire-based research tools, 3, 12 while objective testing with spirometry may be a challenge in community-based epidemiological surveys. 11 With notable exceptions, such as the Burden of Lung Disease (BOLD), 13 surveys of the prevalence of CRDs conducted in LMICs often have major limitations (such as relying on patient-reported disease or symptom questionnaires), and report very varied estimates of prevalence. 2, In addition, many existing surveys focus on one condition (e.g. the BOLD study detects COPD, 13 the International Study of Asthma and Allergies in Childhood (ISAAC) detects symptoms of asthma and allergy in children 40 ) and rarely look for the broad range of less common causes of CRD (such as interstitial lung disease, bronchiectasis, lung cancer and complications post tuberculosis) or attempt to identify the phenotypes of asthma and COPD, which are increasingly regarded as important to understanding and managing the conditions. 41 Effective health policies related to CRD can only be developed if we know the true burden of asthma, COPD and other CRDs in the community. Funded by the National Institute for Health Research (NIHR), RESPIRE is a Global Health Research Unit focusing on respiratory health in Asia (https://www.ed.ac.uk/usher/respire). Prior to undertaking a comprehensive Four Country ChrOnic Respiratory Disease study (4CCORD) in the partner countries of RESPIRE, we sought to systematically scope the literature to identify existing strategies-that is, definitions, questionnaires, study tools and diagnostics protocols-that have been used to conduct surveys for CRDs in LMICs.
METHODS
A systematic scoping review aims to 'map the key concepts underpinning a research area and the main sources and types of evidence available'. 42 As such, scoping reviews typically address broad questions, potentially include a range of methodologies and do not undertake quality assessment. This contrasts with the focused question of a systematic review, which is answered from a relatively narrow range of qualityassessed studies. 42 Systematic review procedures, as described in the Cochrane Handbook for Systematic Reviews of Interventions, 43 have been adapted to meet the needs of a scoping review. 44, 45 We will follow the six-step framework described by Arksey and O'Malley 42 and subsequently widely endorsed and enhanced in methodological literature. [45] [46] [47] Identifying the research question
The aim of this review is to scope published epidemiological CRD surveys to identify their aims, methodologies and outcomes in order to identify evidence gaps and inform the methodology of the proposed RESPIRE 4CCORD survey on the burden of CRD. Our objectives are therefore to answer the following research questions:
1. What surveys on the prevalence of asthma, COPD and other CRDs have been undertaken in resource-poor settings? 2. What definitions, questionnaires, tests, diagnostic processes and outcomes did the surveys employ? 3. How was the socio-economic burden (from a societal or healthcare perspective) of asthma, COPD and other CRDs estimated in these surveys? 4. What strategies have been used to identify phenotypes of asthma and COPD, or to identify the causes of 'other CRD'?
Identifying relevant studies
We will search MEDLINE, EMBASE, ISI Web of Science, Global Health and WHO Global Health Library using search terms for prevalence AND CRD (COPD OR asthma OR CRD) AND LMICs/low-resource settings, from year 1995 onwards when publication of the Global Initiative for Asthma (GINA), 48 followed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for COPD, 49 provided internationally agreed definitions and diagnostic strategies for the two most common CRDs. The detailed MEDLINE search strategy is shown in Supplementary Table 1 .
Key websites (e.g. http://ghdx.healthdata.org) will be checked for eligible studies. We will follow up references of surveys with methodological papers, and will group papers from the same study (e.g. BOLD, 13 FRESH AIR 4 ). To avoid overlooking relevant local studies, we will not impose language restrictions; translations will be undertaken where possible.
Study selection
Selection criteria and definitions are detailed in Table 1 . Our focus is on surveys conducted in LMICs to study the prevalence of CRD (specifically asthma and COPD but also other CRDs) in randomly sampled communitybased populations of adults. We anticipate that these will incorporate assessment of chronic respiratory symptoms and objective tests, measurement of risk factors for CRD, phenotypes of asthma/COPD or individual, healthcare or societal burden of CRD. We will undertake training at each step (100 randomly selected titles/abstracts or 50 full-text papers will be screened independently by D.A., N.S.H., H.P., E.M.K. and S.J.; they will be repeated until agreement exceeds 90%). After an initial shift to exclude obviously irrelevant titles (D.A., N.S.H.), two reviewers (D.A., N.S.H., S.C., S.-M.L. or E.A.B.) will screen the titles and abstracts, and then undertake full-text screening of potentially relevant papers, with disagreements resolved by discussion between researchers, arbitrated by a third reviewer (H.P., E.M.K. and S.J.) if necessary, and involving the wider research group to agree on conventions that operationalise the inclusion/exclusion criteria (see Table 1 ). The selection process will be undertaken using EndNote software (v9.0) and summarised using a PRISMA flow diagram.
Charting the data Two reviewers (D.A., N.S.H., S.C., S.-M.L. or E.A.B.) will independently extract data onto a piloted customised data extraction form as follows: study metadata, country and populations, sampling strategy, CRD definitions, survey procedure (questionnaires used, spirometry and other measurements), risk factors measured, assessments of individual, societal and health service burden of disease and detection of phenotypes. Our research questions focus on identifying the process (rather than the outcomes) of undertaking surveys of CRD in LMICs, though we will note the prevalence of asthma, COPD and any other CRD identified in the included studies in order to inform future sample size calculations.
We will attempt to contact authors of the included papers for missing or unclear essential information; specifically, we will request copies of questionnaires or study procedures if they are not otherwise available. Multiple publications from the same study will be grouped, and draw on all the relevant publications, including methodological papers. 13 Collating, summarising and reporting the results
We will tabulate the procedures used and identify
•
The strategies used to identify randomly sampled populations in LMICs
The disease definitions used (which may vary over time)
The questionnaires used and tests performed to detect asthma, COPD and/or other CRD 8 in the adult population. The survey procedures may include questionnaires, clinical examination, spirometry and/or other tests. We are also interested in the prevalence of chronic respiratory symptoms, and in surveys that detected phenotypes
Disease definitions
We will include studies that use definitions of CRD from globally recognised guidelines: asthma, 50 COPD 51 or other CRD 8 We define 'chronic' respiratory symptoms as symptoms (such as cough, wheezing and shortness of breath) that have persisted for more than 3 months, or recurred in 'attacks'
Burden of disease We are interested in the population-level surveys of the burden of CRD; this includes symptom burden, use of healthcare resources or societal burden (e.g. absenteeism, loss of earnings)
Phenotypes
We are interested in population-level surveys that have attempted to detect phenotypes of asthma, 50 COPD 51 or the overlap between these conditions 53 in the context of low-resource settings Setting Normally LMICs. Our, focus is surveys undertaken in low-resource contexts, which we anticipate will normally be countries classified by the Organisation for Economic Cooperation and Development as being 'LMIC' at the time of the survey. We may, however, include surveys developed in higher-income countries if the methodology employed was subsequently used in lowresource settings (e.g. BOLD)
Study designs Prevalence surveys, including protocols for surveys COPD chronic obstructive pulmonary disease, CRD chronic respiratory disease, LMICs low-and middle-income countries, BOLD Burden of Lung Disease D. Agarwal et al.
•
Other variables for which information is collected in the included studies, in order to assess individual, societal and healthcare burden of CRD, and the risk factors for disease
• Whether recent surveys have addressed contemporary understanding of asthma/COPD phenotypes 41, 50, 51 and the variables assessed to achieve this in low-resource settings
Consultation
We will convene a workshop of the multidisciplinary research team with representatives from the RESPIRE partners (from Bangladesh, India, Malaysia, Pakistan and Edinburgh), at which the findings of the scoping review will be presented, discussed and interpreted. The conclusions will inform a future RESPIRE 4CCORD study, which will aim to estimate CRD burden in adults in Asian LMICs (initially Bangladesh, India, Malaysia and Pakistan).
Dissemination
We will publish our findings in a peer-reviewed journal following the reporting standards for scoping reviews (PRISMA-ScR) 52 and disseminate widely through our stakeholder groups and using innovative media approaches.
DISCUSSION
Assessment of the true prevalence for asthma, COPD and other CRDs underpins healthcare planning. Policymakers need assessments of the burden of disease if they are to plan and resource services that can accurately diagnose and effectively reduce the burden of CRD. Communication of the burden of CRD will raise awareness amongst stakeholders of the individual and societal impact of respiratory conditions and highlight the importance to communities of addressing potentially modifiable risk factors.
Limitations in currently available estimates of CRD burden in South Asian countries (e.g. relying on symptom questionnaires, or patient-reported diagnoses), hamper advocacy and are a barrier to development of healthcare service. Our scoping review will identify existing strategies used in surveys in LMICs, enabling future surveys to optimise their methodology and provide robust estimates of disease burden. 
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